NovAb

NovAb is a biotechnology company specializing in the discovery and development of next-generation nanobody-based therapeutics. Utilizing its proprietary camelid-derived VHH library and advanced phage display technology, the company focuses on creating high-affinity, stable, and multi-specific antibody fragments. NovAb's pipeline primarily targets oncology and inflammatory diseases, leveraging the unique structural advantages of nanobodies for better tissue penetration and modular design. The company provides both internal drug development and collaborative discovery services to global pharmaceutical partners. Its lead programs include nanobodies targeting PD-L1 and CD47, designed to overcome the limitations of traditional monoclonal antibodies.